https://www.bioworld.com/rss en-us In a recent study, scientists from Stanford University and collaborators aimed to develop a platform for specific tumor-immune cell targeting, focusing on tumor-associated macrophages (TAMs), with the eventual goal of interfacing with existing immune checkpoint inhibitor technologies. http://www.bioworld.com/articles/732625 Tue, 14 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732625-tictacs-remodel-tams-reduce-tumor-burden-and-metastasis 3D illustration of tumor SL Science Holding Ltd. has submitted an orphan drug designation request to the FDA for its γδ T-cell therapy product, Vδ2+ γδ T cells, for the treatment of glioblastoma multiforme. http://www.bioworld.com/articles/732565 Mon, 13 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732565-sl-science-seeks-us-orphan-drug-designation-for-t-cell-therapy Illustration of T cells attacking tumor Cancer researchers are increasingly turning to the microbiome to understand why some patients respond well to treatment while others face severe complications. Gut microbial communities shift during intensive therapies such as bone marrow transplantation, and those changes influence infection risk, immune recovery and long‑term survival. New advances in microbial sequencing and engineering redefine this community as a measurable clinical parameter that can be monitored, modeled, and even therapeutically reshaped to improve outcomes in oncology and other conditions. http://www.bioworld.com/articles/732621 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732621-microbial-ecology-reshapes-cancer-care-diagnostics-and-therapies Illustration of bacteria, microorganisms in the gastrointestinal system Rybodyn Inc. has been awarded $1.3 million from the U.S. Department of War to advance preclinical development of two novel antibody-based therapies for lung cancer. http://www.bioworld.com/articles/732500 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732500-grant-supports-rybodyns-antibody-therapies-for-lung-cancer Lung cancer illustration Urogen Pharma Ltd. has obtained IND approval from the FDA for UGN-501, a next-generation investigational oncolytic virus. A phase I study evaluating intravesical administration of UGN-501 in patients with non-muscle invasive bladder cancer (NMIBC) is expected to begin in the fourth quarter. http://www.bioworld.com/articles/732499 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732499-urogens-ugn-501-gains-ind-clearance-for-bladder-cancer Art concept for bladder A Beijing Mabworks Biotech Co. Ltd. patent describes new antibody-drug conjugates (ADCs) comprising antigen-binding fragments or antibodies targeting delta-like protein 3 (DLL3) linked to a cytotoxic drug potentially useful for the treatment of small-cell lung cancer (SCLC). http://www.bioworld.com/articles/732495 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732495-beijing-mabworks-biotech-discloses-new-dll3-targeting-adcs Researchers from Hainan Medical University and collaborators have demonstrated that PGE2-EP2/EP4-G α s-PKA signaling drove the expansion of immunosuppressive VSIG4-high macrophages and promoted immunotherapy resistance in colorectal cancer (CRC). http://www.bioworld.com/articles/732486 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732486-targeting-vsig4-high-tams-in-colorectal-cancer-immunotherapy Illustration of cancer inside colon Coregen Inc. has obtained IND clearance from the FDA for CRG-150, a novel adoptive cell therapy targeting SRC-3 (steroid receptor coactivator 3). http://www.bioworld.com/articles/732484 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732484-coregens-crg-150-gains-ind-clearance-for-solid-tumors Illustration of lymphocytes attacking cancer cell LTZ Therapeutics Inc.’s LTZ-232 has gained IND clearance from the FDA, enabling initiation of a phase I study in patients with advanced metastatic colorectal cancer and other solid tumors. http://www.bioworld.com/articles/732481 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732481-fda-clears-ind-for-ltz-therapeutics-ltz-232 Macrophage and cancer cell Cancer researchers are increasingly turning to the microbiome to understand why some patients respond well to treatment while others face severe complications. Gut microbial communities shift during intensive therapies such as bone marrow transplantation, and those changes influence infection risk, immune recovery and long‑term survival. New advances in microbial sequencing and engineering redefine this community as a measurable clinical parameter that can be monitored, modeled, and even therapeutically reshaped to improve outcomes in oncology and other conditions. http://www.bioworld.com/articles/732480 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732480-microbial-ecology-reshapes-cancer-care-diagnostics-and-therapies Illustration of bacteria, microorganisms in the gastrointestinal system Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma Inc./Pfizer Inc.), and possibly to ADCs more broadly. Urothelial cancer drug Padcev, which targets the cell adhesion molecule Nectin-4, was approved in 2019 and is currently one of Pfizer’s top 10 medicines and vaccines, generating $1.94 billion in 2025. http://www.bioworld.com/articles/732450 Tue, 07 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732450-target-high-but-uptake-defective-state-identified-in-adc-resistance 3D rendering of an antibody-drug conjugate Children’s Hospital of Fudan University, Sydney Children’s Hospital and the University of Sydney have jointly patented new antibody-drug conjugates comprising an antibody targeting GD2 ganglioside covalently linked to cytotoxic drugs potentially useful for the treatment of osteosarcoma. http://www.bioworld.com/articles/732411 Mon, 06 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732411-chinese-australian-researchers-disclose-gd2-ganglioside-targeting-adcs Brightpath Biotherapeutics Co. Ltd. has submitted an IND application to the FDA to initiate a phase I trial of BP-2202 in the U.S. (NCT07667868). http://www.bioworld.com/articles/732376 Fri, 03 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732376-brightpath-files-ind-application-for-bp-2202-for-multiple-myeloma Illustration of CAR T Two papers published in the July 1, 2026, issues of Nature and Nature Cancer have reported on preclinical and early clinical data with glycoprotein nonmetastatic melanoma protein B (GPNMB)-targeting CAR T cells in two separate solid tumor types. Nature and Nature Cancer have reported on preclinical and early clinical data with glycoprotein nonmetastatic melanoma protein B (GPNMB)-targeting CAR T cells in two separate solid tumor types.]]> http://www.bioworld.com/articles/732356 Thu, 02 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732356-with-gpnmb-car-t-makes-further-inroads-in-solid-tumors Illustration of CAR T Researchers at East China Normal University and collaborators reported the discovery and optimization of a series of SUCNR1 antagonists for cancer immunotherapy. http://www.bioworld.com/articles/732335 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732335-sucnr1-antagonist-reverses-tumor-immune-suppression 3D Rendering of tumor microenvironment Aptevo Therapeutics Inc. has been awarded a $1.5 million research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling work for APVO-451, Aptevo’s trispecific antibody-like immunotherapy candidate for solid tumors. http://www.bioworld.com/articles/732334 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732334-grant-supports-aptevos-immunotherapy-apvo-451-for-solid-tumors Illustration of cancer cell in crosshairs being destroyed Salubris Biotechnology Co. have reported the development of novel antibody-drug conjugates (ADCs) against glypican-3 (GPC3), an oncofetal glycoprotein overexpressed in approximately 70%-85% of hepatocellular carcinoma (HCC) cases but absent in normal adult tissues. http://www.bioworld.com/articles/732189 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732189-gpc3-targeting-adc-for-hcc-shows-superior-efficacy-in-preclinical-models Combotope Therapeutics ApS has established a strategic research collaboration with Boehringer Ingelheim Pharma GmbH & Co. KG that will leverage Combotope’s proprietary SMART-Phage platform to generate highly tumor-selective antibodies for next-generation cancer therapies. http://www.bioworld.com/articles/732136 Thu, 25 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732136-combotope-and-boehringer-ingelheim-partner-in-cancer Lab glassware and antibodies art concept Researchers from Bristol Myers Squibb Co. (BMS) presented preclinical data on BMS-986453 (tunlucabtagene autoleucel), a dual-targeting BCMA×GPRC5D CAR T-cell therapy, in models of multiple myeloma. http://www.bioworld.com/articles/732132 Thu, 25 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732132-bmss-dual-car-t-cell-therapy-shows-efficacy-in-multiple-myeloma MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene Corp. Ltd.’s preclinical anticancer bispecific T-cell engager (TCE) assets. The deal, announced June 21, will grant Singapore-based K2 exclusive rights to develop and commercialize Antengene’s ATG-106 outside of mainland China, Hong Kong, Macau and Taiwan. http://www.bioworld.com/articles/732152 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732152-k2-nabs-two-antengene-bispecific-tces-in-2b-license-option-deal Photo of two people shaking hands near lab equipment Rin Institute Inc. has disclosed antibody-drug conjugates consisting of an antibody targeting insoluble fibrin conjugated to MMAE through a plasmin-cleavable linker reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/732123 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732123-rin-institute-discovers-new-insoluble-fibrin-targeting-adcs Light chain multiple myeloma (LCMM) is a cancer driven by malignant plasma cells that produce excessive pathogenic free light chains (FLCs) that may cause kidney dysfunction and form amyloid deposits in key organs, thus leading to poor outcomes. Ab Studio Inc.’s CATA-001 is a bispecific antibody targeting both CD38 and aggregated light chains (ALs) designed to deplete CD38+ plasma cells and clear both circulating and tissue-deposited pathogenic FLC aggregates for the treatment of LCMM and AL amyloidosis. http://www.bioworld.com/articles/732095 Mon, 22 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732095-cata-001-yields-promising-results-for-light-chain-multiple-myeloma Red and blue bispecific antibodies MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene Corp. Ltd.’s preclinical anticancer bispecific T-cell engager (TCE) assets. The deal, announced June 21, will grant Singapore-based K2 exclusive rights to develop and commercialize Antengene’s ATG-106 outside of mainland China, Hong Kong, Macau and Taiwan. http://www.bioworld.com/articles/732090 Mon, 22 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732090-k2-nabs-two-antengene-bispecific-tces-in-2b-license-option-deal Photo of two people shaking hands near lab equipment Evaxion A/S has developed EVX-04, an AI-designed DNA vaccine encoding 1β endogenous retroviruses (ERVs)-derived antigenic fragments to induce broad antigen-specific T-cell responses targeting acute myeloid leukemia blasts expressing ERV antigens. http://www.bioworld.com/articles/732031 Fri, 19 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732031-evaxion-shares-data-from-characterization-of-evx-04 Calidi Biotherapeutics Inc. has received pre-IND regulatory feedback from the FDA on Calidi’s IND-enabling preclinical plans and clinical strategy for CLD-401. The parties agreed on key aspects of the CMC and nonclinical programs, as well as the overall design for the proposed first-in-human study. http://www.bioworld.com/articles/731994 Wed, 17 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731994-calidi-receives-pre-ind-feedback-from-fda-on-cld-401 Oncolytic virus concept illustration A patent from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. has divulged new antibody-drug conjugates comprising antibodies covalently linked to N-myristoyltransferase 1 (NMT1) inhibitors for potential use in the treatment of cancer. N-myristoyltransferase 1 (NMT1) inhibitors for potential use in the treatment of cancer.]]> http://www.bioworld.com/articles/731971 Tue, 16 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731971-hengrui-pharmaceuticals-prepares-new-adcs-for-cancer Clinical responses to BCMA- or GPRC5D-directed T-cell engagers in relapsed/refractory multiple myeloma (MM) are often limited by disease relapse and antigen escape, underscoring the need for dual-targeting strategies that enhance durability while mitigating cytokine-driven toxicity. http://www.bioworld.com/articles/731964 Tue, 16 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731964-bendao-biotechnology-reports-data-on-btl-101-in-multiple-myeloma-models Multiple myeloma art concept Harnessing an oncolytic signal and redirecting it against the tumor itself could be developed as a selective strategy for certain cancer types, as occurs with ErbB hyperactivity, a form of signaling that drives many carcinomas. Inspired by this idea, scientists at Stanford University have engineered a virus that replicates only in ErbB-hyperactive ovarian cancer cells. This allowed them to precisely kill this specific tumor population, achieving greater efficacy and safety than previous oncolytic viruses. http://www.bioworld.com/articles/731852 Tue, 16 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731852-signal-rewiring-turns-ovarian-cancer-against-itself Illustration of cancer on ovary Researchers from Peking University and Bristar Immunotech Ltd. recently presented the development of a synthetic T-cell receptor and antigen receptor-T (STAR-T) cell therapy targeting leukocyte immunoglobulin-like receptor B4 (LILRB4) for acute myeloid leukemia (AML). http://www.bioworld.com/articles/731934 Mon, 15 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731934-dual-epitope-anti-lilrb4-star-t-cell-therapy-for-r-r-aml Illustration of acute myeloid leukemia (AML) cells in the blood stream Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or antigen-binding fragments targeting V-set domain-containing T-cell activation inhibitor 1 (VTCN1, B7-H4) and tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) linked to cytotoxic drug. They are described as potentially useful for the treatment of cancer. http://www.bioworld.com/articles/731868 Fri, 12 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731868-fortvita-and-innovent-patent-new-anti-trop2-b7-h4-adcs